Table 2.
Association of ACEi/ARB use with 28-day mortality
| Model | Recipients of Kidney Transplant (n=459) | Patients on Dialysis (n=1052) | ||||
|---|---|---|---|---|---|---|
| Nonusers | Users | P Value | Nonusers | Users | P Value | |
| Event rate (events)a | 5.8 (55) | 4.9 (33) | 7.2 (184) | 6.0 (60) | ||
| Model 1b | Reference | 0.85 (0.55 to 1.31) | 0.46 | Reference | 0.85 (0.63 to 1.13) | 0.27 |
| Model 2c | Reference | 1.03 (0.65 to 1.64) | 0.89 | Reference | 1.05 (0.75 to 1.45) | 0.79 |
| Model 3d | Reference | 1.11 (0.69 to 1.81) | 0.66 | Reference | 1.04 (0.73 to 1.47) | 0.82 |
| Model 4e | Reference | 1.12 (0.69 to 1.83) | 0.64 | Reference | 1.04 (0.73 to 1.47) | 0.84 |
Presented are the hazard ratios (95% confidence intervals) in transplant recipients and patients on dialysis, separately, unless otherwise indicated. ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.
a
Event rate (events) per 100 person-weeks.
b
Model 1, crude.
c
Model 2, model 1 plus age, sex, and frailty.
d
Model 3, model 2 plus systolic BP, diabetes, and heart failure.
e
Model 4, model 3 plus anti-inflammatory therapy and antiviral therapy.